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Dear Editor 
Granulocyte - macrophage colony stimulating factor 
and bronchial asthma - A hypothesis for novel 
therapeutic options 
Current concepts of the pathogenesis of bronchial 
asthma indicate an inflammatory model (1). In this 
context, modulation of peripheral and airway 
eosinophils should play a role in the pathophysiology 
of asthma (1). Similarly, neutrophils are also impli- 
cated and neutrophil depletion ablates late phase 
response in bronchial asthma (2). Granulocyte - 
macrophage colony stimulating factor (GM-CSF) 
stimulates production of neutrophils, eosinophils and 
monocytes of peripheral blood and bone marrow (1). 
Recent studies from Japan have shown increased 
GM-CSF production by mononuclear cells from the 
peripheral blood of patients with bronchial asthma 
(1). The same study also stressed the importance of 
GM-CSF in the proliferation and survival of inflam- 
matory cells in bronchial asthmatics. The acquisition 
of bronchial asthma by recipients of bone marrow 
from donors with clinically symptomatic asthma, 
following bone marrow transplantation has been 
reported previously (3). 
The findings that bronchial asthma can be trans- 
mitted by bone marrow transplantation and that 
GM-CSF production is increased in the peripheral 
blood of bronchial asthmatics should have important 
implications; as logically, neutrophil and eosinophil 
depletion should reduce the inflammatory compo- 
nent of bronchial asthma. Depletion of neutrophils 
abolishes bronchial hyper-responsiveness in dogs and 
rabbits (4). Corticosteroids are effective in the treat- 
ment of bronchial asthma and they are known to 
produce eosinopenia (5). Do these findings suggest a 
role for GM-CSF in asthmatics? It has been hypoth- 
esized that the haemopoietic growth factors (e.g. 
GM-CSF) and drugs such as gold salts and chloro- 
quine have opposing actions in the proliferation of 
bone marrow myeloid progenitors in rheumatoid 
arthritis, producing leucopenia and hence decreased 
inflammatory response (6). Methotrexate inhibits 
myeloid colony formation in vitro (6). It is interesting 
to note that drugs such as gold salts, hydroxy- 
chloroquine and methotrexate are also used in the 
treatment of bronchial asthma (2). Hence, the oppos- 
ing effects of GM-CSF and gold salts, hydroxy- 
chloroquine and methotrexate on the bone marrow 
precursor cells should be true in bronchial asthmatics 
as well. 
Corticosteroids act in asthmatics by their effect on 
GM-CSF by inhibiting GM-CSF at the transcription 
level, by inhibiting GM-CSF’s permissive action on 
eosinophil survival and also by decreasing eosinophil 
production in bone marrow (5). The blocking effects 
of antibodies of GM-CSF on eosinophils in bronchial 
asthmatics has been demonstrated (1). Does this 
suggest the opening of a novel direction in bronchial 
asthma therapy? There is a need for further studies in 
asthmatics with drugs presumed to have opposing 
effects on GM-CSF. 
J. C. TONY 
Kasturba Medical College Hospital 
Manipal, India 
10 May 1995 
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Dear Editor 
Idiopathic pulmonary haemosiderosis (IPH) 
We read with interest the case reported by Bouros 
et al. (l), as we reported a similar case of IPH in a 
young male (2). Our patient was an ‘occasional’ 
smoker whose mother kept a meticulous diary detail- 
ing her son’s smoking habits. He had relapses and on 
each occasion he had commenced smoking about 6 
weeks previously. Twelve years after initial presenta- 
tion, 10 years after stopping smoking and 9 years 
since corticosteroids were stopped, he remains 
clinically fit and healthy. 
Tobacco smoke has a profound effect both in vitro 
and in vivo on immune function. We suggested the 
possibility that smoking may have contributed to 
these relapses and advised that it would be wise to 
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check the smoking habits of any young adult who 
develops this condition. 
J. B. BUICK, R. C. LOWRY AND M. RILEY 
Respiratory Investigation Centre 
Belfast City Hospital, U.K. 
2 June 1995 
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Dear Editor 
Air filtration units 
We would like to thank Warner and Warner for 
their comments (1) on our paper entitled ‘Domicili- 
ary air filtration units .’ (2). We wholeheartedly 
agree with their views on the excessive technological 
claims which are being made with regard to the 
benefits of simplistic devices aimed at minimizing 
allergen exposure and subsequent therapeutic expec- 
tations. It is quite important that journals are also 
prepared to publish negative studies in this field, 
otherwise such approaches (air filters, dehumidi- 
fiers, ionisers and vacuum cleaners) could become 
an accepted part of asthma management, without 
scientific merit. 
However, we must contest their views with regard 
to air sampling and their explanation for the inability 
of our measurements to quantify airborne levels of 
dust mite. Previous reports from other centres have 
suggested that mite allergen can only be quantita- 
tively detected in the air after significant disturbance 
of the reservoir (carpets etc.). In addition, the com- 
mercially available assays have a lower limit of 
sensitivity of 5 ng ml - ’ Derp I when the linear part 
o&the standard curve is used for analysis (3). Use 
of the non-linear part of the standard curve is scien- 
tifically inappropriate and, at best, only semi- 
quantitative. 
The major determining factor in the low airborne 
levels of mite allergen is the large particle size and 
fast settling rate of- Der p I, compared to animal 
allergens for example, which have been repeatedly 
and reliably measured from airborne samples. 
Currently available mite assays do have satisfac- 
tory sensitivity to quantitatively measure levels of 
allergen in dust collected for reservoir samples 
(vacuumed carpets/mattresses etc.), but they remain 
insufficiently sensitive to measure airborne levels. In 
our paper, we tried to overcome this lack of sensitiv- 
ity by increasing the volume of air, and therefore 
sample load, without a corresponding increase in the 
diluent volume, thus increasing the concentration of 
allergen for assay by at least 15fold. Warner and 
Warner’s suggestion that using high volume samplers 
filters the air and therefore dilutes the sample com- 
pared to using lower flow samplers is unlikely to be 
relevant as, even with high flow samples, the volume 
of air sampled is only 10 m3 which is equivalent to 
less than one-quarter of a normal room volume. Any 
small effect of filtering this proportion of room air 
would be more than compensated for by the extra 
antigen load produced by a larger sample volume, on 
the filter and subsequently in the assay. 
We have also analysed the effect of sonication on 
samples which they have recommended. This study 
demonstrated no increase in analysed concentrations 
after sonication of the sample (4) which again is not 
surprising in view of the well demonstrated, rapid 
solubility of the mite allergen. 
Unfortunately the inability to reliably measure 
airborne Der p I will prevent satisfactory assessment 
of devices claimed to produce a reduction in the 
airborne mite allergen. It will be necessary to con- 
tinue to use reservoir sampling as the standard of 
assessment of exposure until more sensitive Derp I 
assays are available. 
C. J. WARBUTON, R. McL. NIVEN AND 
C. A. C. PICKERING 
North West Lung Centre 
Wythenshawe Hospital, Manchester, U.K. 
20 June 1995 
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Dear Editor 
Banning smoking in hospitals 
Many will sympathize with the motives behind Dr. 
Kayente’s call for a total ban on smoking in hospitals 
